600 patients67,035 observations120 daysLIVE

Patient P-01332

Synthetic patientNBL-101 · Day 90 · 55–64 · M · baseline S14Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 45 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 44%, therapy response 41 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 48 (trajectory left the model); the side effect would have been reported on day 57 — 9 days of warning.

Still taking it?

7 of 8 scheduled doses in the last 60 days are biologically confirmed (88%); 1 were logged but show no dose signature. Dose signature: resting HR +5 bpm, HRV −10 ms.

last 8 doses · green confirmed · amber logged only · red missed
Plan for this patient
not yet offeredstrongowner · Study nursereview day 93Human Model →
Next action
ME-01 Monitoring Escalation
83% probability of improvement
Kept if

100% of 284 similar trajectories improved after ME-01; if this one does, discontinuation risk is expected to fall from 67% to ~49%. Keeping fat low is worth 6.5 GI points a day on its own. Losing this patient costs €57k; the intervention costs €180.

Daily to-dos in the companion
  • 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊Electrolyte solution, one sachet after any loose stool
Adherence
57% worsening

Dose is being missed; nothing else works until this is fixed.

Changes the plan if

GI burden above 69 for 3 days within the onset window

LLIFE OS insight
grounded · add an LLM key for prose

P-01332 is on day 90 of NBL-101 (EC-03, baseline S14): response unstable, tolerance stable, GI unstable. Over 14 days response moved -14 and GI -2; discontinuation risk is 67%. The state is in the failing basin, heading towards failing, after diverging from the model on day 48.

Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Poor metabolizer, Low butyrate capacity, Low microbial diversity, Baseline state S14, Cluster EC-03 (high response / high intolerance), Adherence < 60%; butyrate capacity 28/100, diversity 1.9. Pushing it down: Enterococcus faecium 16.88% (LPS load) (-28.5), Low butyrate capacity (-23.3), Dietary fat load (-20.5). Pulling it up: GI Support Protocol GI-04 (+28.4), Dietary Support Protocol NP-02 (+24.5). From the daily log: fat +6.5 GI next day, simple carbs +6 GI next day, histamine +5.2 GI next day.

Past actions: NP-02 on day 32 → improved (15%); GI-04 on day 54 → improved (22%).

Next: ME-01 — 100% of 284 similar trajectories improved, 83% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.

Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
67%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 GI symptom burden −15% vs expectedDietary Support Protocol NP-02
  5. Day 48 Trajectory diverged from predictionObserved response fell below the model's expected path.
  6. Day 48 Tolerance state changedUnstable → Improving
  7. Day 53 GI-04 recommendedGI Support Protocol GI-04
  8. Day 54 Patient acceptedStarted GI-04 in the companion
  9. Day 62 GI symptom burden −22% vs expectedGI Support Protocol GI-04
  10. Day 68 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days
  • Treatment adherence-3
  • GI instability-2
  • Toxicity+2

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: symptom burden −15%
  • GI Support Protocol GI-04Day 53
    Result: symptom burden −22%
LIFE OS recommendation
83%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Daily trackers

Asset settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
61.2/100
stable · +1.2 vs previous 14 d
Toxicity
Blood
40.6/100
stable · +1.1 vs previous 14 d
Sleep quality
Wearable
37.5/100
stable · +1.0 vs previous 14 d
Energy level
Daily log
3.2/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log
5.9/10
stable · -0.2 vs previous 14 d
Steps
Wearable
6,428
improving · +459 vs previous 14 d
Adherence
Companion
56.8 %
worsening · -19.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 23 from the failing basin, 66 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 67 similar · onset 3 d · confidence 71%
  • SC-12 Supportive Compound
    65% improved among 46 similar · onset 6 d · confidence 71%
  • CR-01 Clinician Review
    100% improved among 9 similar · onset 5 d · confidence 71%
Would not help
  • Keep fat low
    GI +6.5 next day on high-intake days · n 28
  • Keep simple carbs low
    GI +6 next day on high-intake days · n 26
  • Keep histamine low
    GI +5.2 next day on high-intake days · n 23
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +6.5detractor · 95%
  • Simple carbohydrates
    +6detractor · 95%
  • Histamine load
    +5.2detractor · 95%
  • Spicy / capsaicin
    -2.6no signal · 43%
  • Insoluble fibre
    +0.3no signal · 15%
  • Alcohol
    +0.3no signal · 15%

DeepGene damage signature

The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

Damage score · retest day 90
85/100
vs baseline (day 0)
+4
1 improved · 9 worsened
synthetic signature · consistent with this patient's biology
  • 3 opportunists above range: Enterococcus faecium, Streptococcus gallolyticus, Clostridioides difficile
  • 6 keystone species absent
  • Shannon 1.64 (expected ≥ 3)
  • 10 resistance genes
  • Host DNA fragmentation atypical
  • Tissue recycling index 60
Pathogens / opportunists3/5
Keystone species6/8
from 5
Diversity2/2
Metabolic modules1/4
from 0
Vitamin synthesis6/7
from 4
Oral translocation1/1
Host DNA1/1
Tissue recycling1/1
Central mechanisms2/2
Species dominance1/1
from 0
Virulence factors6/6
from 5
Antibiotic resistance genes10/10
from 8
Genetic predisposition2/2
Opportunists above range
Enterococcus faecium 16.88% AR
Streptococcus gallolyticus 3.376% AR
Clostridioides difficile 3.376% AR
Keystone species absent
Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale, Faecalibacterium prausnitzii
Capacity
Shannon 1.64 · butyrate 282 CPM · SCFA 603
H2S above band
6 vitamins below
Host & mechanisms
host DNA fragmentation atypical
tissue recycling 60/100
oral translocation 7.65% AR
molecular_mimicry above
estrobolome above
10 resistance genes · 6 virulence factors

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 61 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 28/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 56
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 41
  • Autonomic recovery 25
    • WearableResting HR 79 bpm
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 1.9 · butyrate capacity 28/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
45 ms
Sleep
7.3 h
Steps
7,014
Resting HR
79 bpm
Daily log: GI score 61, nutritional resilience 36, adherence 57.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0134522%S02AD-05improved36
P-0165023%S14BR-03improved38
P-0176836%S17CR-01improved58
P-0187735%S01CR-01improved61
P-0160034%S09CR-01improved58
P-0151432%S13CR-01improved46
P-0169931%S19CR-01improved55
P-0170830%S14CR-01improved63
P-0169727%S13CR-01improved56
P-0172524%S01CR-01improved62
P-0179424%S13CR-01improved51
P-0158524%S17DT-01improved50